Autologous peripheral blood stem cell transplantation using MEAM regimen with HAART for refractory and relapsed HIV associated lymphoma: multicentered phase2 clinical trial

Autologous peripheral blood stem cell transplantation using MEAM regimen with HAART for refractory and relapsed HIV associated lymphoma: multicentered phase2 clinical trial - Auto PBSCT for refractory and relapsed HIV associated lymphoma (ARL209)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003159

Enrollment

Registered

2010-02-10

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory and relapsed HIV associated lymphoma

Interventions

autologous stem cell transplantation using MEAM regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HIV positive refractory to first line chemotherapy and relapsed HIV associated lymphoma

Exclusion criteria

Exclusion criteria: heart failure, live dysfunction, renal dysfunction uncontrollable opportunistic infection uncontrollable diabetes uncontrollable HIV infection by HAART

Design outcomes

Primary

Measure	Time frame
Engraftment and survival at day 100 post transplantation	—

Secondary

Measure	Time frame
1year and 2year overall survival progression free survival event free survival therapy related toxicity remission rate number of CD4 positive cell and quantity of HIV-RNA	—

Countries

Japan

Contacts

Public ContactShotaro Hagiwara

National Center for Global Health and Medicine Division of Hematology

shagiwar@hosp.ncgm.go.jp+81-3-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026